Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(19 sites)

China

Novartis Investigative Site, Hefei, Anhui

Novartis Investigative Site, Guangzhou, Guangdong

Novartis Investigative Site, Nanning, Guangxi

Novartis Investigative Site, Guiyang, Guizhou